Last updated on October 2018

First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors


Brief description of study

The purpose of this study is to determine whether a Monoclonal Antibody both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors

Clinical Study Identifier: NCT03110107

Contact Investigators or Research Sites near you

Start Over

Site 0006

Local Institution
North Sydney, Australia
  Connect »